Looking like top-line between ESC and EASD is a likely possibility. And if this is the case, then database lock by end of August and prior to ESC is also likely.

European Society of Cardiology (ESC) August 31 to Sept 4, 2019; Paris, France. There are two regular abstracts listed for apabetalone or BETonMACE to be presented at ESC 2019 as well as a Resverlogix sponsored symposium. Only poster titles are available right now. 

Sat August 31, 2019 Symposium "Epigenetics: A new pathway to tackle residual risk?" See here and here. 

Mon Sept 2, 2019, 14:00: BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial

Tues Sept 3, 2019, 08:30: Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism

European Association for the Study of Diabetes (EASD): Sept 16-20, 2019; Barcelona, Spain. There is a poster presentation on September 17th, 2019 entitled "Apabetalone modulates Th1 responses in diabetes and CVD through intrinsic and extrinsic mechanisms: in vitro and in human studies." See abstract here.